Johnson & Johnson: CAPLYTA tops adjunctive MDD antipsychotics in network meta-analysis

Key highlights
  • Bayesian network meta-analysis of 10 randomized, placebo‑controlled adjunctive MDD trials compared lumateperone (CAPLYTA) versus aripiprazole, brexpiprazole, cariprazine and quetiapine XR.
  • Lumateperone showed the largest effects on efficacy: MADRS change MD -4.71 (95% CrI -5.78, -3.63), MADRS response OR 2.33 (95% CrI 1.77, 3.05), MADRS remission OR 2.22 (95% CrI 1.57, 3.07), and CGI‑S change MD -0.60 (95% CrI -0.74, -0.46).
  • On weight outcomes lumateperone had no statistically significant mean weight gain versus placebo plus ADT (MD -0.08; 95% CrI -0.30, 0.13) and a lower odds of ≥7% weight increase (OR 0.41; 95% CrI 0.04, 1.42).
  • The NMA was funded by Janssen Research & Development, LLC.

Study and methods

A Bayesian network meta-analysis pooled doses from 10 randomized, double‑blind, placebo‑controlled adjunctive MDD trials to compare five FDA‑approved atypical antipsychotics—aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine XR—using a star‑shaped network anchored on antidepressant therapy (ADT) plus placebo; outcomes assessed included MADRS change, response, remission, CGI‑S, and select safety measures (weight, ≥7% weight gain, akathisia, somnolence).

Efficacy results

Lumateperone showed the largest effects across efficacy endpoints: MADRS change MD −4.71 (95% CrI −5.78, −3.63); MADRS response OR 2.33 (95% CrI 1.77, 3.05); MADRS remission OR 2.22 (95% CrI 1.57, 3.07); and CGI‑S change MD −0.60 (95% CrI −0.74, −0.46); pairwise comparisons anchored to lumateperone favored it versus most comparators for MADRS and CGI‑S and versus all but one comparator for response and remission.

Safety and tolerability

Lumateperone showed no statistically significant mean weight gain versus placebo+ADT (MD −0.08; 95% CrI −0.30, 0.13) and had lower odds of ≥7% weight increase (OR 0.41; 95% CrI 0.04, 1.42), ranking most favorably on weight outcomes (100% probability of superiority on mean weight change); it was the only treatment judged comparable to placebo+ADT for akathisia risk (OR 3.78; 95% CrI 0.40, 17.17), while somnolence risk was higher than placebo across all treatments including lumateperone (OR 5.90; 95% CrI 2.86, 11.50).

Context and limitations

The analysis used indirect comparisons across trials that may differ in design and populations, so results should be interpreted alongside individual trial data and clinical judgement; the NMA was funded by Janssen Research & Development, LLC and presented at the Neuroscience Education Institute Spring Congress (May 1–3, 2026).

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

19 November 2026
Johnson & Johnson files for CAPLYTA approval in bipolar mania

Two Phase 3 trials found symptom improvement by Day 3, sustained through Week 3; approval would add another adult use.

10 November 2026
Johnson & Johnson reports positive Phase 3 mania results for CAPLYTA

A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.

8 September 2026
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026

24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.

27 April 2026
Johnson & Johnson: FDA approves CAPLYTA sNDA to reduce schizophrenia relapse risk

FDA approved sNDA for CAPLYTA (lumateperone) to prevent relapse in schizophrenia. Phase 3 randomized‑withdrawal: 63% lower relapse risk (HR 0.37); 84% relapse‑free at 6 months; safety consistent.

6 November 2025
Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment

FDA approves CAPLYTA® as adjunctive therapy for major depressive disorder, showing significant symptom improvement and safety in trials, with potential for remission.